Puma Biotechnology Inc (NYSE:PBYI) was downgraded by equities researchers at BidaskClub from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.
Shares of Puma Biotechnology (NYSE:PBYI) traded down $1.90 during mid-day trading on Tuesday, reaching $101.10. The company had a trading volume of 1,681,600 shares, compared to its average volume of 1,121,087. Puma Biotechnology has a 1 year low of $28.35 and a 1 year high of $136.90.
An institutional investor recently raised its position in Puma Biotechnology stock. Janus Henderson Group PLC raised its stake in shares of Puma Biotechnology Inc (NYSE:PBYI) by 1.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,890,901 shares of the biopharmaceutical company’s stock after buying an additional 33,270 shares during the quarter. Janus Henderson Group PLC owned about 5.04% of Puma Biotechnology worth $226,435,000 at the end of the most recent reporting period. Institutional investors own 80.98% of the company’s stock.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
Receive News & Ratings for Puma Biotechnology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology Inc and related companies with MarketBeat.com's FREE daily email newsletter.